DaVita (DVA) and The Competition Head-To-Head Analysis

DaVita (NYSE:DVA) is one of 233 public companies in the “Healthcare Providers & Services” industry, but how does it compare to its rivals? We will compare DaVita to related businesses based on the strength of its earnings, dividends, profitability, risk, valuation, analyst recommendations and institutional ownership.

Volatility and Risk

DaVita has a beta of 0.87, meaning that its share price is 13% less volatile than the S&P 500. Comparatively, DaVita’s rivals have a beta of 0.98, meaning that their average share price is 2% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and recommmendations for DaVita and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DaVita	0	3	4	0	2.57
DaVita Competitors	1851	7707	13270	815	2.55

DaVita presently has a consensus price target of $235.86, indicating a potential upside of 29.84%. As a group, “Healthcare Providers & Services” companies have a potential upside of 15.71%. Given DaVita’s stronger consensus rating and higher possible upside, equities analysts clearly believe DaVita is more favorable than its rivals.

Insider & Institutional Ownership

90.1% of DaVita shares are held by institutional investors. Comparatively, 56.8% of shares of all “Healthcare Providers & Services” companies are held by institutional investors. 1.9% of DaVita shares are held by insiders. Comparatively, 15.0% of shares of all “Healthcare Providers & Services” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares DaVita and its rivals revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
DaVita	$13.64 billion	$746.80 million	13.38
DaVita Competitors	$21.01 billion	$288.54 million	7.40

DaVita’s rivals have higher revenue, but lower earnings than DaVita. DaVita is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares DaVita and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
DaVita	6.49%	-225.93%	5.42%
DaVita Competitors	-7.69%	-141.09%	-1.47%

Summary

DaVita beats its rivals on 8 of the 13 factors compared.

About DaVita

DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company offers integrated care and disease management services to patients in risk-based and other integrated care arrangements; clinical research programs; physician services; and comprehensive kidney care services. Further, it engages in the provision of acute inpatient dialysis services and related laboratory services; and transplant software business. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.